Precision immunotherapy to improve sepsis outcomes
About The Study: Among patients with sepsis, precision immunotherapy targeting macrophage activation–like syndrome and sepsis-induced immunoparalysis improved organ dysfunction by day 9 compared with placebo.
Corresponding Author: To contact the corresponding author, Evangelos J. Giamarellos-Bourboulis, MD, PhD, email egiamarel@med.uoa.gr.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.24175)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.24175?guestAccessKey=9fca94d2-11b0-47a7-820e-3165a1ff136b&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=120825
END